Loading...
•
Dec 31, 2025
Beam Therapeutics Q4 2025 Earnings Report
Beam Therapeutics reported fourth quarter 2025 financial results, highlighting significant net income driven by a gain on sale of an equity method investment and strengthened its cash position.
Key Takeaways
Beam Therapeutics generated strong fourth quarter net income primarily due to a gain on sale of an equity method investment, while operating expenses remained relatively stable year over year. The company ended the quarter with a significantly strengthened cash position of over 1245210000.
Reported net income of 244297000 for Q4 2025, driven by a 255146000 gain on sale of an equity method investment.
License and collaboration revenue increased to 114109000 from 30067000 in the prior year quarter.
R&D expenses slightly decreased year over year to 99275000.
Ended the quarter with 1245210000 in cash, cash equivalents, and marketable securities.
Revenue by Segment
Forward Guidance
Beam expects its cash, cash equivalents and marketable securities as of December 31, 2025, combined with the anticipated 200000000 minimum drawdown from the Sixth Street facility, to fund operations into mid-2029 while advancing key clinical, regulatory, and commercial milestones.
Positive Outlook
- Cash runway expected into mid-2029.
- Anticipated minimum 200000000 drawdown from Sixth Street facility.
- BLA submission for risto-cel expected as early as year-end 2026.
- Updated Phase 1/2 data for BEAM-302 expected by end of Q1 2026.
- IND filing for BEAM-304 anticipated in 2026.
Challenges Ahead
- Risto-cel BLA submission timing remains subject to regulatory progress.
- BEAM-302 pivotal development path still being defined.
- BEAM-304 remains preclinical pending IND filing.
- Future milestone-based funding under credit facility is conditional.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...